Coherus BioSciences, Inc. (CHRS)
Data as of , from SEC Form 4 filings.
No open-market insider trades (90d)Watch CHRS
See up to 3 months of CHRS. The 7-day demo opens the 1M and 3M ranges and puts CHRS on your watchlist.
Start 7-day demoLatest CHRS insider trades
About Coherus BioSciences, Inc. (CHRS)
The SEC lists Coherus BioSciences, Inc. under CIK 0001512762, in biological products (no diagnostic substances). It is grouped with Health Care companies on this site.
CHRS Form 4 activity by transaction type, last 90 days
No Form 4 activity for CHRS in the last 90 days.
CHRS insider transactions (Form 4)
5114 Form 4 filings on record, the earliest from Dec 17, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Ali J. Satvat | Grant or award | Common Stock | 30,000 footnote F1 | $0.00 | - | |
| Ali J. Satvat | Grant or award | Stock Option (Right to Buy) | 60,000 | $0.00 | - | |
| ||||||
| Rita A. Karachun | Grant or award | Common Stock | 30,000 footnote F1 | $0.00 | - | |
| Rita A. Karachun | Grant or award | Stock Option (Right to Buy) | 60,000 | $0.00 | - | |
| ||||||
 Lee Nisley Newcomer | Grant or award | Stock Option (Right to Buy) | 60,000 | $0.00 | - | |
| Lee Nisley Newcomer | Grant or award | Common Stock | 30,000 footnote F1 | $0.00 | - | |
| ||||||
 Michael Lee Ryan | Grant or award | Stock Option (Right to Buy) | 60,000 | $0.00 | - | |
| Michael Lee Ryan | Grant or award | Common Stock | 30,000 footnote F1 | $0.00 | - | |
| ||||||
| Jill O'Donnell-Tormey | Grant or award | Stock Option (Right to Buy) | 60,000 | $0.00 | - | |
| Jill O'Donnell-Tormey | Grant or award | Common Stock | 30,000 footnote F1 | $0.00 | - | |
| ||||||
| Mats Wahlstrom | Grant or award | Common Stock | 30,000 footnote F1 | $0.00 | - | |
| Mats Wahlstrom | Grant or award | Stock Option (Right to Buy) | 60,000 | $0.00 | - | |
| ||||||
| Charles W. Newton | Grant or award | Common Stock | 30,000 footnote F1 | $0.00 | - | |
| Charles W. Newton | Grant or award | Stock Option (Right to Buy) | 60,000 | $0.00 | - | |
| ||||||
| Bryan J. McMichael - Officer | Derivative | Stock Option (Right to Buy) | 100,000 | - footnote F5 | - | |
| Bryan J. McMichael - Officer | Derivative | Stock Option (Right to Buy) | 25,000 | - footnote F5 | - | |
| Bryan J. McMichael - Officer | Derivative | Stock Option (Right to Buy) | 25,000 | - footnote F5 | - | |
| Bryan J. McMichael - Officer | Derivative | Stock Option (Right to Buy) | 25,000 | - footnote F5 | - | |
| Bryan J. McMichael - Officer | Derivative | Stock Option (Right to Buy) | 15,000 | - footnote F5 | - | |
| Bryan J. McMichael - Officer | Derivative | Stock Option (Right to Buy) | 30,000 | - footnote F5 | - | |
| Bryan J. McMichael - Officer | Grant or award | Stock Option (Right to Buy) | 100,000 | - footnote F5 | - | |
| Bryan J. McMichael - Officer | Grant or award | Stock Option (Right to Buy) | 25,000 | - footnote F5 | - | |
| Bryan J. McMichael - Officer | Grant or award | Stock Option (Right to Buy) | 25,000 | - footnote F5 | - | |
| Bryan J. McMichael - Officer | Grant or award | Stock Option (Right to Buy) | 25,000 | - footnote F5 | - | |
| Bryan J. McMichael - Officer | Grant or award | Stock Option (Right to Buy) | 15,000 | - footnote F5 | - | |
| Bryan J. McMichael - Officer | Grant or award | Stock Option (Right to Buy) | 30,000 | - footnote F5 | - | |
| ||||||
| Dennis M. Lanfear - Officer | Derivative | Stock Option (Right to Buy) | 200,000 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Derivative | Stock Option (Right to Buy) | 400,000 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Derivative | Stock Option (Right to Buy) | 450,000 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Derivative | Stock Option (Right to Buy) | 500,000 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Derivative | Stock Option (Right to Buy) | 500,000 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Derivative | Stock Option (Right to Buy) | 125,000 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Derivative | Stock Option (Right to Buy) | 402,500 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Derivative | Stock Option (Right to Buy) | 402,500 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Derivative | Stock Option (Right to Buy) | 225,000 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Grant or award | Stock Option (Right to Buy) | 200,000 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Grant or award | Stock Option (Right to Buy) | 400,000 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Grant or award | Stock Option (Right to Buy) | 450,000 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Grant or award | Stock Option (Right to Buy) | 500,000 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Grant or award | Stock Option (Right to Buy) | 500,000 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Grant or award | Stock Option (Right to Buy) | 402,500 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Grant or award | Stock Option (Right to Buy) | 402,500 | - footnote F3 | - | |
| Dennis M. Lanfear - Officer | Grant or award | Stock Option (Right to Buy) | 225,000 | - footnote F3 | - | |
| ||||||
| Dennis M. Lanfear - Officer | Grant or award | Common Stock | 375,000 footnote F1 | $0.00 | - | |
| Dennis M. Lanfear - Officer | Grant or award | Stock Option (Right to Buy) | 750,000 | $0.00 | - | |
| ||||||
| Bryan J. McMichael - Officer | Grant or award | Common Stock | 112,500 footnote F1 | $0.00 | - | |
| Bryan J. McMichael - Officer | Grant or award | Stock Option (Right to Buy) | 225,000 | $0.00 | - | |
| ||||||
| Bryan J. McMichael - Officer | Tax withholding / forfeiture | Common Stock | 1,715 footnote F1 | $1.55 | $3K | |
| ||||||
| Dennis M. Lanfear - Officer | Tax withholding / forfeiture | Common Stock | 11,839 footnote F1 | $1.55 | $18K | |
| ||||||
| Paul Reider - Officer | Tax withholding / forfeiture | Common Stock | 2,073 | $1.61 | $3K | |
Item 8.01, 9.01
Item 7.01, 8.01, 9.01
Item 1.01, 1.02, 2.03, 9.01
Item 2.02, 9.01
CHRS insider trading FAQ
What is the latest insider trade for CHRS?
Coherus BioSciences, Inc. (CHRS) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-06-10. The full record for CHRS runs to 14 Form 4 filings, the earliest from 2024-12-17. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CHRS stock?
No insider purchases of CHRS were filed in the last 90 days.
How many insiders are selling CHRS stock?
No insider sales of CHRS were filed in the last 90 days.
Where can I see CHRS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CHRS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Ali J. Satvat view on EDGAR
- - Rita A. Karachun view on EDGAR
- - Lee Nisley Newcomer view on EDGAR
- - Michael Lee Ryan view on EDGAR
- - Jill O'Donnell-Tormey view on EDGAR
- - Mats Wahlstrom view on EDGAR
- - Charles W. Newton view on EDGAR
- - Bryan J. McMichael view on EDGAR
- - Dennis M. Lanfear view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where CHRS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CHRS with a 7-day demo
- CHRS on your watchlist
- Every CHRS Form 4 filing on record
- Up to 3 months of CHRS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
